StemRIM

StemRIM Net Debt / EBITDA

The Net Debt to EBITDA of StemRIM (4599.T) as of Nov 22, 2026 is -53.72. In the previous year, Net Debt to EBITDA was 4.60 — a change of -1,268.86% (lower).

Net Debt / EBITDA

-53.72

YoY

-1,268.86%

Last updated:

Net Debt to EBITDA of StemRIM is 2023 -53.72 . Net Debt to EBITDA of StemRIM was 2022 4.60 . It decreases by -1,268.86% lower compared to the previous year.

The StemRIM Net Debt / EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt / EBITDA
Date
Net Debt / EBITDA
Jan 1, 2019
3.43 JPY
Jan 1, 2020
-25.19 JPY
Jan 1, 2021
18.48 JPY
Jan 1, 2022
4.60 JPY
Jan 1, 2023
-53.72 JPY
The StemRIM Net Debt / EBITDA history
YEARNet Debt / EBITDAYoY
-53.72-1,268.86%
4.60-75.13%
18.48-173.36%
-25.19-835.40%
3.43—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

StemRIM Stock analysis

What does StemRIM do? StemRIM, Inc. develops and researches regeneration-inducing medicine based on a new action mechanism to promote functional regeneration and healing of damaged biological tissue. The company's main product is stem cell regeneration-inducing medicine, which delivers therapeutic effects similar to regenerative medicine without requiring living cells or tissues. StemRIM's primary customers are medical institutions and healthcare providers seeking advanced treatment options for tissue repair and regeneration. The company generates revenue through the sale of its stem cell regeneration-inducing medicine to these healthcare segments. StemRIM focuses on research and development of medicines that can restore lost function in biological tissue caused by injury or illness. The firm's product line centers around its stem cell regeneration-inducing medicine, which eliminates the need for using living cells in treatment. This innovative approach targets medical professionals and institutions looking for efficient regenerative solutions. StemRIM's business model relies on selling its patented medicine to healthcare providers for clinical applications. The company's revenue streams come from the commercialization of its stem cell regeneration-inducing medicine, which is designed to provide regenerative therapy without cell-based treatments. StemRIM's target market includes hospitals and medical facilities that require advanced regenerative treatments for patients with tissue damage. The firm's research and development efforts are centered on creating medicines that can promote healing through a novel mechanism, differentiating their product from traditional regenerative medicine approaches. StemRIM is one of the most popular companies on Eulerpool.

Frequently Asked Questions about StemRIM stock

Net Debt to EBITDA of StemRIM is -53.72 in 2023.

Net Debt to EBITDA of StemRIM changed from 4.60 to -53.72, representing a -1,268.86% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to EBITDA StemRIM since 2006 – with annual values, charts, and detailed analysis.

Net Debt/EBITDA measures how many years it would take to repay all debt using EBITDA. Lower ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to EBITDA's StemRIM with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — StemRIM

All Key Metrics — StemRIM